top of page

Technology

Introducing QinoTrans

Disease modifying treatments for neurodegenerative diseases are currently limited by the exclusion of large molecule therapeutics by the blood-brain barrier. We have identified through our proprietary BBB platform QinoTrans a highly diversified portfolio of endogenous brain transporters that have the potential to facilitate and greatly improve CNS uptake of intravenous drugs.

Qinotto Colored Icon version transparent.png

A Powerful Discovery Platform: QinoTrans 

Screen Shot 2024-09-10 at 11.28_edited.j

First platform to identify genetic determinants of transport leading to discovery of novel transporters or anti-transporters

  • Correct age or disease-related dysfunction of the BBB

  • Enhance delivery of therapeutics to the brain

“Trojan Horse” Shuttles

Screen Shot 2024-09-11 at 4.49.11 PM.png

​"Trojan Horse" Shuttles make use of endogenous receptors to deliver therapeutic molecules to cells that would otherwise be inaccessible .
​
Each of these receptors may preferentially deliver proteins to specific cell types of interest to enable cell-type specific targeting of therapies
​

bottom of page